Skip to main content

03-04-2021 | Semaglutide | Commentary | Article

STEP 2: A higher semaglutide dose in people with type 2 diabetes

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).

Keep up with the latest results from the STEP trials

About the speaker

Ildiko Lingvay

Ildiko Lingvay is Professor in the Division of Endocrinology and the Department of Population and Data Sciences at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, USA.

Full biography

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Image Credits